| Titre : | Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study (2006) |
| Titre traduit : | (Le résultat du traitement par buprénorphine chez les patients héroïnomanes à diagnostic double : une étude rétrospective.) |
| Auteurs : | G. GERRA ; C. LEONARDI ; A. D'AMORE ; STREPPAROLA G. ; FAGETTI R. ; C. ASSI ; A. ZAIMOVIC ; LUCCHINI A. |
| Type de document : | Article : Périodique |
| Dans : | Progress in Neuro-Psychopharmacology and Biological Psychiatry (Vol.30, n°2, 2006) |
| Article en page(s) : | 265-272 |
| Langues: | Anglais |
| Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
| Mots-clés : |
Thésaurus géographique ITALIEThésaurus mots-clés HEROINE ; TRAITEMENT ; BUPRENORPHINE ; SUBSTITUTION ; TRAITEMENT DE MAINTENANCE ; ETUDE RETROSPECTIVE ; COMORBIDITE ; DEPRESSION ; TROUBLES DE LA PERSONNALITE ; SCHIZOPHRENIE ; DIAGNOSTIC ; PSYCHOPATHOLOGIE |
| Résumé : | The present study compared retrospectively in a clinical non-experimental setting the efficacy of buprenorphine (BUP) in different subgroups of dually diagnosed and non-dually diagnosed opioid-dependent patients: all the subjects included in the study showed severe long-lasting heroin addiction and 68.4% were affected by psychiatric comorbidity. Participants (206) (mean age 32.2+8.9, 177 males-29 females) were applicants to a long-term buprenorphine treatment program (mean doses 7.9+0.42 mg). Aim of the study was to evaluate dual diagnosis variables possibly influencing retention rate and abstinence from illicit drugs. The patients were divided into 5 subgroups on the basis of dual diagnosis: group 1: major depression (MD) 29.61%; group 2: generalized anxiety (GAD) (11.2%); group 3: personality disorders (PD), antisocial-borderline (21.84%); group 4: schizophrenia (SC)(6.3%); group 5: substance use disorder without overt psychiatric comorbidity (SUD) (31.1%). Group 1 patients affected by MD showed the highest retention rate at 12 months (72.1%) in comparison with the other groups of patients: group 2 GAD (39.1%), group 3 PD (17.8%), group 4 SC (7.7%) and group 5 SUD, without comorbidity (45.3%) (p=0.006, p |
| Domaine : | Drogues illicites / Illicit drugs |
| Refs biblio. : | 37 |
| Affiliation : |
Addiction Treatment Centre, AUSL Parma. Italie. Italy. |
| Numéro Toxibase : | 1301553 |
| Centre Emetteur : | 13 OFDT |
| Cote : | A02677 |
Accueil
